md-medicaldata

Authors

 

Predrag Marić¹, Branko Košević¹, Dušica Stamenković^2
1 Department of urology, Military Medical Academy, Belgrade, Serbia
² Department of anesthesiology and intensive care, Military Medical Academy, Belgrade, Serbia

 

• The paper was received on 28.11.2015. / Accepted on 01.12.2015.

 

Abstract

 

Renal cell carcinoma is one of the more frequently represented malignancies. It is the third most frequent urological cancer with participation of 2-3% of all adult malignancies. In addition to hereditary diseases its appearance is often associated with smoking. Lately clinical presentation is of little importance for its diagnosis which is usually accidental during routine ultrasound examinations. The major role in confirming the diagnosis, making treatment decisions or the type of surgical techniques has the multi slice CT scan. In advanced renal carcinomas the patient prognosis without treatment is poor. Considering treatment modalities, surgery is the most effective method of treatment. Depending on the size and location of the tumor, partial or radical nephrectomy is performed. For decades, radical nephrectomy presented the standard surgical treatment option  for treatment of localized renal carcinoma. However in the last decade for treatment of localized renal cell carcinoma, partial nephrectomy is more practiced, as well as laparoscopic and minimal invasive surgical techniques which offer the same oncological results as radical nephrectomy but with decreased morbidity. Approximately 20-30% of patients present with metastasis at the time the diagnosis of renal carcinoma is first made. In the remaining two thirds, 20-30 % develop metastasis after surgical treatment. Metastasis are the main cause of death in these patients. Of all diagnosed patients with renal carcinoma 30-40% die of this illness.

 

 

References

 

1. Lipovorth L, Tarone RE, Lund L, McLaughlin JK. Epidemiologic characteristic and risk factors for renal cell cancer. Clin Epidemiol 2009;1:33-43
2. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg calassification of renal cell tumors. J Pathol 1997;183:131-3.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C,Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer 2008;127:2893-917.
4. Pascual D, Borque A. Epidemiology of kidney cancer . Adv Urol 2008;782381
5. King SC, Pollack LA, Li J, King JB, Master VA. Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010. J Urol  2014; 191: 1665-70.
6. Lungberg BC, Campabell SC, Choi HY, et al. Ethiology and epidemiology. In: Kirkali Z,Mulders P,editors. Kidney cancer. Paris, France: International Consultation on Urological Diseases-European Association of Urology; 2011.
7. Chow WH, Linehan WM, Devesa SS. Re: Rising incidence of small renal masses: a need to reasses treatment effect.J Natl Cancer Inst 2007;99:569-70
8. Leiba A, Kark JD, Afek A, Derazne E, Barchana M, Tzur D, et al. Adolescent obesity and paternal country of origin predict renal cell carcinoma: a cohort study of 1.1 million 16 to 19-year-old males. J Urol 2013, 189: 25–9.
9. Verine J, Pluvinage A, Bousquet G, et al. Hereditary  renal cell cancer syndromes: an update of a systematic review. Eur Urol 2010;58:701-10.
10. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG JR et al. Innovations and challenges in renal cancer:summary statement from the Third Cambridge Conference. Cancer 2009;115:2247-2251.
11. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an expirience  of 405 cases. Am J Surg Pathol 2002;26:281-91.
12. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89:604-14.
13. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma(mRCC): a literature review. Cancer Treat Rev 2008;34:193-205.
14. Dyer R, Disantis DJ, McClennan BL. Simplified imaging approuch for evaulation of the solid renal mass in adults. Radiology 2008;247:331-43.
15. Hock LM, Lynch J, Balaji KC. Increasing  incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of the Surveillance, Epidemiology and End Results Program data. J Urol 2002;167:57-60.
16. Dushene DA, Lotan Y, Cadeddu JA, Sagalowsky AI, Koeneman KS. Histopatology of surgically managed renal tumors: analysis of a contemporary series. Urology 2003;62:827-30.
17. Jemal A,Siegel R, Xu J, Ward E. Cancer statistic.2010. CA Cancer J Clin 2010;60:277-300.
18. Robson CJ. Radical nephrectomy for renal cell carcinoma . J Urol  1963;89:37-41.
19. Ljunberg B, Almdari FI, Holmberg G, Granfors T, Duchek M. Radical nephrectomy is stil preferable in the treatment of localized  renal cell carcinoma. Eur Urol  1998;33:79-85.
20. Weinberg AC ,  Woldu SL , Wen T ,  Deibert CM ,  Korets R,  Badani KK. Utilization and perioperative complications of laparoscopic cryoablation vs. robotic partial nephrectomy for localized renal tumors Int Braz J urol 2015;41: 473-485,
21. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron- sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75:1236-42.
22. Butler BP, Novick AC, Miller DP, Campbel SA, Licht MR. Managment  of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology 1995;45:34-40.
23. Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for T1 tumours based on an international multicenter experience. Urol 2004;171(6pt1):2181-5.
24. Weight CJ, Larson BT, Gao T, et al. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology. 2010;76:631-7.
25. 25. Crepel M, Jeldres C, Sun M et al. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1a renal cell carcinoma. Urology   2010;76: 883-8.
26. Becker F, Siemer S, Humke U, Hack M, Ziegler M, Stockle M. Elective nephron sparing surgery should become standard treatment for small unilateral renal cell carcinoma: Long-term survival data of 216 patients. Eur Urol.2006;49:308-13.
27. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patines with renal cortical tumours: retro spective cohort study. Lancet Oncol. 2006;7:735.
28. Thompson RH, Boorjian SA, Lohse CM, et  al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol.2008;179:468.
29. Dash A, Vickers AJ, Schachter LR, et al. Comparison of outcomes in elective partial vs radical nephrectomy of clear cell renal cell carcinoma of 4-7 cm. BJU Int. 2006; 97:939.
30. Mitchell RE, Gilbert SM, MurphyAM, et al. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 centimetres or larger. Urology. 2006;67:260.
31. Leibovich BC, Blute ML, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma  between 4 and 7 cm results in outcome  similar to radical nephrectomy. J Urol. 2004;171:1066.
32. Lai TC,  Ma WK, Yiu MK. Partial nephrectomy for T1 renal cancer can achieve an equivalent oncological outcome to radical nephrectomy with better renal preservation: the way to go. Hong Kong Med J 2015;21:Epub 23 Oct 2015
33. Hadjipavlou M, Khan F,  Fowler S,  Joyce A,  Keeley FX, Sriprasad S;  BAUS Sections of Endourology and Oncology. Partial vs radical nephrectomy for T1 renal tumours: an analysis from the British Association of Urological Surgeons Nephrectomy Audit. BJU Int. 2015 Mar 6.
34. 34.Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective randomized EORTC intergroup phase 3 study comparing oncologic outcome of elective nephron sparing surgery and radical nephrectomy for low stage renal cell carcinoma. Eur Urol. 2011; 59:543-52.
35. Sun M, Trinh QD, Bianchi M, Hansen J, Hanna N, Abdollah F, Shariat SF, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI. A non-cancer-related survival benefit is associated with partial nephrectomy.Eur Urol. 2012;61:725-31.
36. MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, et al; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel.Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. Eur Urol. 2012;62:1097-117.
37. Jang HA,  Kim JW,  Byun SS,  Hong SH,  Kim YJ,  Park H,  Yang KS, Cho S, Cheon J,Kang SH. Oncologic and Functional Outcomes after Partial Nephrectomy Versus Radical Nephrectomy in T1b Renal Cell Carcinoma: A Multicenter, Matched Case-Control Study in Korean Patients. Cancer Research and Treatment : Official Journal of Korean Cancer Association 2015; crt.2014.122.
38. Ficcara V, Novara G, Iafrate M ,et al.Proposal for reclassification  of the TNM   stading system in patients  with locally advanced (pT3-4) renal cell  carcinoma  according  to the  cancer-related  outcome. Eur Urol 2007;51:722-31.
39. Zini L,Perrotte P, Jeldres C, et al.Nephrectomy improves the survival of patients with locally  advanced  renal cell carcinoma .BJU Int 2008;102:1610-4.
40. Kim SP, Alt AL, Veight C J, et al. Indipendent validation  of the 2010 American  Joint Committee of Cancer TNM clasification  for renal cell carcinoma :result from a large,single institution cohort.J,Urol 2011;185:2035-9.
41. Amato RJ. Chemoterapy for  renal  cell carcinoma. Semin Oncol 2000;27:177-86.
42. Kwak C, Park YH, Jeong CW, Lee SE, Ku JH. Metastasectomy  without  systemic therapy in metastatic  renal cell carcinoma: comparison  with conserative treatment. Urol Int 2007;79:145-51.
43. Harshman LC, Kroeger N, Rha SY, Donskov F,et al. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.Clin Genitourin Cancer. 2014 ;12:335-40.
44. Hutson TE, Escudier B, Esteban E, Bjarnason GA,et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients withmetastatic renal cell carcinoma. J Clin Oncol. 2014;32:760-7.

PDF Marić P. et al. • MD-Medical Data 2015;7(4): 291-294